A Study of Mirdametinib in People With Central Nervous System Tumors

Full Title

Phase 1/2 Trial of Mirdametinib in Patients with MAPK Pathway Mutant Central Nervous System Tumors

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Anna Piotrowski’s office at 212-610-0483.

Protocol

26-103

Phase

Phase I/II (phases 1 and 2 combined)

Investigator

Anna F. Piotrowski

Co-Investigators

Eli L. Diamond

Diseases

Brain Tumors, Primary › Primary Central Nervous System Lymphoma

Locations

Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau

ClinicalTrials.gov ID

NCT07539441

ClinicalTrials.gov

Visit ClinicalTrials.gov for full clinical trial description